• The modern concept of premenstrual syndrome 
To content

The modern concept of premenstrual syndrome 

HEALTH OF WOMAN.2015.6(102):22–27; doi 10.15574/HW.2015.102.22 

The modern concept of premenstrual syndrome 

Veropotvelyan P. M., Bondarenko A. O., Veropotvelyan M. P., Zhuravleva S. A.

«Inter-provincial center of medical genetics and prenatal diagnosis», Krivoy Rog 

This article presents a modern view on premenstrual syndrome. Taking into account the polyetiology and multivariatiron of premenstrual syndrome various treatments are considered. Use of oral contraceptives containing progestin component such as drospirenone and non-traditional methods of treatment, in particular lazeromagnitoreflexotherapy is discussed. 

Key words: premenstrual syndrome, oral contraceptives, drospirenone, bulimia nervosa. 


1. Frank RT. 1931. The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry 26:1053–7. http://dx.doi.org/10.1001/archneurpsyc.1931.02230110151009

2. Lopez LM, Kaptein AA, Helmerhorst FM. 2012. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2:CD006586. http://dx.doi.org/10.1002/14651858.CD006586.pub4.

3. Leminen H, Paavonen J. 2013. PMS and PMDD. Duodecim. 129(17):1756–63.

4. Oelkers W. 2004. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol. Cell. Endocrinol. 17(1–2):255–61.

5. Rapkin AJ, Winer SA. 2008. The pharmacologic management of premenstrual dysphoric disorder. Expert Opin. Pharmacother 9:1–17.

6. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N et al. 2009. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants: a review. Clin. Ther. 31:1426–53. http://dx.doi.org/10.1016/j.clinthera.2009.07.009; PMid:19698902

7. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. 2004. The effectiveness of GnRHa with and without “add-back” therapy in treating premenstrual syndrome: a meta-analysis. Br. J. Obstet. Gynaecol. 111(6):585–93.

8. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin: no 15: Premenstrual syndrome. Obstet. Gynecol. 95(4):1–9. 2000.

9. Fathizadeh N, Ebrahimi E, Valiani M, Tavakoli N, Yar MH. 2010. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J. Nurs. Midwifery Res. 15(1):401–5.

10. Yonkers KA, O’Brien PM, Eriksson E. 2008. Premenstrual syndrome. Lancet. 371(9619):1200–10.

11. Grady-Weliky TA. 2003. Clinical practice. Premenstrual dysphoric disorder. N. Engl. J. Med. 348:433–8.

12. Hirschberg AL, Naessйn S, Stridsberg M, Bystrцm B, Holtet J. 2004. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol. Endocrinol. 19(2):9–87.

13. Kuznetsova IV, Dil VV. 2014. Premenstrual syndrome and eating misbehavion. Akusherstvo I ginecologiya. Obstetrics and Gynecology 1:5–11(in Russian)

14. Wyatt KM, Dimmock PW, Jones PW, O’Brien PM. 1999. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: a systematic review. Br. Med. J. 318(7195):1375–81.

15. World Health Organization (WHO). International classification of diseases. 10th ed. Geneva. WHO. 1996.

16. Unanyan AL, Arakelov SE, Polonskaya LS, Guriev TD, Morozova VD. Premenstrual syndrome aspects of classification, diagnosis, and treatment. IM Sechenov First Moscov Statet Medical University, Russia. City Cinical Hospital Fifty-Three. Moscov, Russia. Peoples Friendship University of Russia, Moscov.

17. Reed SC, Levin FR, Evans SM. 2008. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder). Horm. Behav. 54(1):185–93.

18. Di Giulio G, Reissing ED. 2006. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J. Psychosom. Obstet. Gynaecol. 27(4):201–10.

19. Villarejo C, Fernбndez-Aranda F, Jimйnez-Murcia S, Peсas-Lledу E, Granero R, Penelo E et al. 2012. Lifetime obesity in patients with eating disorders: increasing prevalence, clinical and personality correlates. Eur. Eat Disord. Rev. 20(3):250–4.

20. Thomas JJ, Vartanian LR, Brownell KD. 2009. The relationship between eating disorder not otherwise specified (EDNOS) and officially recognized eating disorders: meta-analysis and implications for DSM. Psychol. Bull. 135(3):407–33. http://dx.doi.org/10.1037/a0015326

21. Eddy KT, Dorer DJ, Franko DL, Tahilani K, Thompson-Brenner H, Herzog DB. 2008. Diagnostic crossover in anorexia nervosa and bulimia nervosa: implications for DSM-V. Am. J. Psychiatry 165(2):245–50. http://dx.doi.org/10.1176/appi.ajp.2007.07060951

22. Miller KK. 2011. Endocrine dysregulation in anorexia nervosa update. J. Clin. Endocrinol. Metab. 96(10):2939–49.

23. Keen-Rhinehart E, Ondek K, Schneide JE. 2013. Neuroendocrine regulation of appetitive ingestive behavior. Neuroendocr. Sci. 7:13.

24. Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. 2013. The role of «mixed» orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. Int. J. Endocrinol. 2013:483145.

25. Jocken JWE, Blaak EE. 2008. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol. Behav. 94:219–30. http://dx.doi.org/10.1016/j.physbeh.2008.01.002; PMid:18262211

26. Santollo J, Katzenellenbogen BS, Katzenellenbogen JA, Eckel LA. 2010. Activation of ER is necessary for estradiol’s anorexigenic effect in female rats. Horm. Behav. 58:872–7. http://dx.doi.org/10.1016/j.yhbeh.2010.08.012; PMid:20807534 PMCid:PMC2982904

27. Butera PC. 2010. Estradiol and the control of food intake. Physiol. Behav. 99:175–80. http://dx.doi.org/10.1016/j.physbeh.2009.06.010; PMid:19555704 PMCid:PMC2813989

28. Hirschberg AL. 2012. Sex hormones, appetite and eating behaviour in women. Maturitas 71(3):248–56. http://dx.doi.org/10.1016/j.maturitas.2011.12.016; PMid:22281161

29. Nohara K, Zhang Y, Waraich RS, Laque A, Tiano JP, Tong J et al. 2011. Early-life exposure to testosterone programs the hypothalamic melanocortin system. Endocrinology 152(4):1661–9. http://dx.doi.org/10.1210/en.2010-1288; PMid:21303958 PMCid:PMC3060636

30. Clegg DJ, Brown LM, Zigman JM, Kemp CJ, Strader AD, Benoit SC et al. 2007. Estradiol-dependent decrease in the orexigenic potency of ghrelin in female rats. Diabetes 56(4):1051–8. http://dx.doi.org/10.2337/db06-0015; PMid:17251274

31. Monteleone P, Fabrazzo M, Tortorella A, Martiadis V, Serritella C, Maj M. 2005. Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. Psychoneuroendocrinology 30(3):243–50. http://dx.doi.org/10.1016/j.psyneuen.2004.07.004; PMid:15511598

32. Sundblad C, Landйn M, Eriksson T, Bergman L, Eriksson E. 2005. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J. Clin. Psychopharmacol 25(1):85–8. http://dx.doi.org/10.1097/01.jcp.0000150222.31007.a9

33. Wang M, Hammarbдck S, Lindhe BA, Bдckstrцm T. 1995. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet. Gynecol. Scand. 74:803–8. http://dx.doi.org/10.3109/00016349509021201; PMid:8533564

34. Brown J, O’Brien PM, Marjoribanks J, Wyatt K. 2009. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 2:CD001396.

35. Steiner M, Pearlstein T, Cohen LS, Endicott J, Korn-stein SG, Roberts C et al. 2006. Expert guidelines for the treatment of severe PMS, PMDD, and co morbidities: the role of SSRIs. J. Womens Health (Larchmt). 15:57–69. http://dx.doi.org/10.1089/jwh.2006.15.57; PMid:16417420

36. Wyatt K, Dimmock P, Jones P, Obhrai M, O’Brien S. 2001. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. Br. Med. J. 323(7316):776–80. http://dx.doi.org/10.1136/bmj.323.7316.776

37. Joffe H, Petrillo LF, Viguera AC, Gottshcall H, Soares CN, Hall JE, Cohen LS. 2007. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J. Clin. Psychiatry 68(12):1954–62. http://dx.doi.org/10.4088/jcp.v68n1218

38. Sitruk-Ware R. 2008. Pharmacological profile of progestins. Maturitas 61(1–2):151–7.

39. Verma RK, Chellappan DK, Pandey AK. 2014, Mar 12. Review on treatment of premenstrual syndrome: from conventional to alternative approach. J. Basic Clin. Physiol. Pharmacol.

40. Kuznetsova IV, Konovalov VA. 2008. Prolonget combinet oral contraceptive drospirenone in the treatment of premenstrual syndrome. Problems of reproduction 4:28–31.

41. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. 2006. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am. J. Obstet. Gynecol. 156:1311–9. http://dx.doi.org/10.1016/j.ajog.2006.05.012; PMid:16796986

42. Reynolds CJ, Buckley JD, Weinstein P, Boland J. 2014. Are the dietary guidelines for meat, fat, fruit and vegetable consumption appropriate for environmental sustainability? A review of the literature. Nutrients 6(6):2251–65. http://dx.doi.org/10.3390/nu6062251; PMid:24926526 PMCid:PMC4073148

43. Berga SL, Loucks TL. 2006. Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann. N. Y. Acad. Sci. 1092:114–29. http://dx.doi.org/10.1196/annals.1365.010; PMid:17308138

44. Vane AM, Voznesenskaya TG. 2007. Depression in neurological practive. M, MIA: 265. In Russ.

45. Naessйn S, Carlstrцm K, Bystrцm B, Pierre Y, Hirschberg AL. 2007. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology 32(5):548–54. http://dx.doi.org/10.1016/j.psyneuen.2007.03.008; PMid:17475412

46. Bertolini S, Elicio N, Cordera R, Gapitanio GL, Montagna G, Croce S et al. 2007. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstet. Gynecol. Scand. 66(4):327–32.